GRS News

Will revision of the EU Medical Device Directive mean more trials at more cost but more reward?"

Five of the ten largest medical device markets in the World are in Western Europe; Germany, France, UK, Italy and Spain with each of these major markets feeling the tensions between economic downturn, Governments seeking to contain healthcare costs, patients demanding ever better interventions and a regulatory environment under revision. For companies operating in the sector, a stable regulatory and economic landscape are key to encouraging investment in the innovation required to develop the sort of efficiencies in technology and medical services that render leading edge care affordable.

Whilst the medical device industry recognised that change was necessary to ensure patient safety in light of such events as the PIP breast implant scandal, are all the changes welcome news or are they just a mechanism that makes the barrier to innovation harder to cross?

Greer Deal will share her insights into the before and after situation for companies with regards to the recent revision of the EU Med Tech Directive and also the possible implications of the New Regulations which the EU Commission will cast their votes on 22nd October 2013.  She will look at the implications of these changes for medical technology companies.  Do the changes mean a greater cost to developing innovative technologies?  Will there also be potential for a larger reward?

This event is free to attend, pre-registration is essential and can be made via the One Nucleus website